



CLAIMS

1. An imidazo[1,2-c]pyrimidinylacetic acid derivative of the formula (I), its tautomeric or stereoisomeric form, or a salt thereof:



5 wherein

R¹ represents



in which

n represents an integer of 0 to 6;

10 Q₁ represents -NH-, -N(C₁-₆ alkyl)-, or -O-;


Y represents hydrogen, C₃-₈ cycloalkyl optionally substituted by C₁-₆ alkyl, C₃-₈ cycloalkyl fused by benzene, aryl or heteroaryl, wherein said aryl and heteroaryl are optionally substituted at a substitutable position with one or more substituents selected from the group consisting of cyano, halogen,

nitro, guanidino, pyrrolyl, sulfamoyl, C₁₋₆ alkylaminosulfonyl, di(C₁₋₆ alkyl)aminosulfonyl, phenyloxy, phenyl, amino, C₁₋₆alkylamino, di(C₁₋₆)-alkylamino, C₁₋₆ alkoxy carbonyl, C₁₋₆ alkanoyl, C₁₋₆ alkanoylamino, carbamoyl, C₁₋₆ alkylcarbamoyl, di-(C₁₋₆alkyl)carbamoyl, C₁₋₆ alkylsulfonyl, C₁₋₆ alkyl optionally substituted by mono-, di-, or tri-halogen, C₁₋₆ alkoxy optionally substituted by mono-, di-, or tri- halogen and C₁₋₆ alkylthio optionally substituted by mono-, di-, or tri- halogen,

or aryl fused by 1,3-dioxolane;


R² represents hydrogen or C₁₋₆ alkyl;

R³ represents hydrogen, halogen, C₁₋₆ alkyl optionally substituted by mono-, di-, or tri-halogen, C₁₋₆ alkoxy optionally substituted by mono-, di-, or tri- halogen,



in which

R^{3a} and R^{3b} independently represent C₃₋₈ cycloalkyl, or C₁₋₆ alkyl optionally substituted by carboxy, C₃₋₈ cycloalkyl, carbamoyl, C₁₋₆ alkylcarbamoyl, aryl-substituted C₁₋₆ alkylcarbamoyl, C₁₋₆ alkylcarbamoyl, di(C₁₋₆alkyl)carbamoyl, C₃₋₈ cycloalkylcarbamoyl, C₃₋₈ heterocyclocarbonyl, C₁₋₆alkylamino, di(C₁₋₆)alkylamino or C₁₋₆ alkoxy,



in which

q represents an integer of 1 to 3;

R^{3c} represents hydrogen, hydroxy, carboxy, or C₁₋₆ alkyl optionally substituted by hydroxy, carboxy or (phenyl-substituted C₁₋₆ alkyl)-carbamoyl;

Xa represents -O-, -S- or -N(R^{3d})-

in which


R^{3d} represents hydrogen or C₁₋₆ alkyl; and

R⁴ represents hydrogen or C₁₋₆ alkyl.

- 5 2. The imidazo[1,2-c]pyrimidinylacetic acid derivative of the formula (I), its tautomeric or stereoisomeric form, or a salt thereof as claimed in claim 1,

wherein

R¹ represents



10

in which

n represents an integer of 0 to 2;

Q₁ represents -NH-, -N(C₁₋₆ alkyl)-, or -O-;

15

Y represents C₃₋₈ cycloalkyl optionally substituted by C₁₋₆ alkyl, C₃₋₈ cycloalkyl fused by benzene, aryl selected from the group consisting of phenyl and naphthyl, or heteroaryl selected from the group consisting of indolyl, quinolyl, benzofuranyl, furanyl and pyridyl, wherein said aryl and heteroaryl are optionally substituted at a substitutable position with one or more substituents selected from the group consisting of cyano, halogen, nitro, pyrrolyl, sulfamoyl, C₁₋₆ alkylaminosulfonyl, di(C₁₋₆ alkyl)aminosulfonyl, phenyloxy, phenyl, C₁₋₆ alkylamino, di(C₁₋₆ alkyl)amino, C₁₋₆ alkoxy-carbonyl, C₁₋₆ alkanoylamino, carbamoyl, C₁₋₆ alkylcarbamoyl, di-(C₁₋₆ alkyl)carbamoyl, C₁₋₆ alkylsulfonyl, C₁₋₆ alkyl optionally substituted by mono-, di-, or tri-halogen, C₁₋₆ alkoxy optionally substituted by mono-, di-, or tri-halogen and C₁₋₆ alkylthio optionally substituted by mono-, di-, or tri-halogen; and

20


25

R² represents hydrogen.

3. The imidazo[1,2-c]pyrimidinylacetic acid derivative of the formula (I), its tautomeric or stereoisomeric form, or a salt thereof as claimed in claim 1,


wherein

- 5 R^3 represents hydrogen, halogen, C_{1-6} alkyl optionally substituted by mono-, di-, or tri-halogen, C_{1-6} alkoxy optionally substituted by mono-, di-, or tri-halogen,



in which

- 10 R^{3a} and R^{3b} independently represent C_{1-6} alkyl optionally substituted by carboxy, C_{3-8} cycloalkyl, carbamoyl, C_{1-6} alkylcarbamoyl, di(C_{1-6} alkyl)carbamoyl, C_{3-8} cycloalkylcarbamoyl, C_{3-8} heterocyclocarbonyl, C_{1-6} alkylamino, di- (C_{1-6} alkyl)amino or C_{1-6} alkoxy,



in which


- 15 R^{3c} represents hydrogen, hydroxy, carboxy, or C_{1-6} alkyl optionally substituted by hydroxy, carboxy or (phenyl-substituted C_{1-6} alkyl)-carbamoyl;

Xa represents -O-, -S- or -N(R^{3d})-,

in which


R^{3d} represents C_{1-6} alkyl.

- 20 4. An imidazo[1,2-c]pyrimidinylacetic acid derivative of the formula (I-i), its tautomeric or stereoisomeric form, or a salt thereof;



wherein

R¹ represents



5

in which

n represents an integer of 0 to 2;

Q₁ represents -NH-, -N(C₁₋₆ alkyl)-, or -O-;

Y represents phenyl, naphthyl, indolyl, quinolyl, benzofuranyl, furanyl or pyridyl,


10

wherein said phenyl, naphthyl, indolyl, quinolyl, benzofuranyl, furanyl and pyridyl are optionally substituted at a substitutable position with one or two substituents selected from the group consisting of cyano, halogen, nitro, phenyloxy, phenyl, C₁₋₆ alkyl optionally substituted by mono-, di-, or

tri-halogen, C₁₋₆ alkoxy optionally substituted by mono-, di-, or tri- halogen
and C₁₋₆ alkylthio optionally substituted by mono-, di-, or tri- halogen;


R² represents hydrogen or C₁₋₆ alkyl;

R³ represents hydrogen, halogen, C₁₋₆ alkyl optionally substituted by mono-, di-, or tri-
halogen, C₁₋₆ alkoxy,



in which

R^{3a} and R^{3b} independently represent C₃₋₈ cycloalkyl, or C₁₋₆ alkyl option-
ally substituted by C₃₋₈ cycloalkyl, carbamoyl, C₁₋₆ alkylcarbamoyl,
(phenyl-substituted C₁₋₆ alkyl)carbamoyl, C₁₋₆ alkylcarbamoyl,
di(C₁₋₆ alkyl)carbamoyl, C₃₋₈ cycloalkylcarbamoyl, C₃₋₈ hetero-
cyclocarbonyl, C₁₋₆alkylamino, di(C₁₋₆alkyl)amino or C₁₋₆ alkoxy,



R^{3c} represents hydrogen, hydroxy, carboxy, or C₁₋₆ alkyl optionally substituted
by hydroxy, carboxy or (phenyl-substituted C₁₋₆ alkyl)carbamoyl; and

R⁴ represents hydrogen or methyl.

5. The imidazo[1,2-c]pyrimidinylacetic acid derivative of the formula (I), its tautomeric or
stereoisomeric form, or a salt thereof as claimed in claim 1, wherein said imidazo[1,2-c]-
pyrimidinylacetic acid derivative of the formula (I) is selected from the group consisting
of:

[7-chloro-5-(4-{{4-(trifluoromethyl)benzoyl}amino}benzyl)imidazo[1,2-c]pyrimidin-8-
yl]acetic acid;

(7-chloro-5-{4-[(3,4-dichlorobenzoyl)amino]benzyl}imidazo[1,2-c]pyrimidin-8-yl)acetic
acid;

{7-chloro-5-[4-(2-naphthoylamino)benzyl]imidazo[1,2-c]pyrimidin-8-yl}acetic acid;

[7-chloro-5-(4-[[[(2E)-3-phenylprop-2-enoyl]amino}benzyl]imidazo[1,2-c]pyrimidin-8-yl)acetic acid;

5 [7-chloro-5-(4-[[[(2E)-3-(4-chlorophenyl)prop-2-enoyl]amino}benzyl]imidazo[1,2-c]pyrimidin-8-yl)acetic acid;

(5-{4-[(3,4-dichlorobenzoyl)amino]benzyl}imidazo[1,2-c]pyrimidin-8-yl)acetic acid; and

[5-(4-{[4-(trifluoromethyl)benzoyl]amino}benzyl)imidazo[1,2-c]pyrimidin-8-yl)acetic acid.

6. A medicament comprising the imidazo[1,2-c]pyrimidinylacetic acid derivative, its tautomeric or stereoisomeric form, or a physiologically acceptable salt thereof as claimed in
10 claim 1 as an active ingredient.

7. The medicament as claimed in claim 6, further comprising one or more pharmaceutically acceptable excipients.

8. The medicament as claimed in claim 6, wherein said imidazo[1,2-c]pyrimidinylacetic acid derivative of the formula (I), its tautomeric or stereoisomeric form, or a physiologically
15 acceptable salt thereof is a CRTH2 antagonist.

9. The medicament as claimed in claim 6 for the treatment and/or prevention of a disorder or disease associated with CRTH2 activity.

10. The medicament as claimed in claim 9, wherein said disorder or disease is selected from the group consisting of asthma, allergic rhinitis, atopic dermatitis and allergic conjunctivitis.

20 11. The medicament as claimed in claim 9, wherein said disorder or disease is selected from the group consisting of Churg-Strauss syndrome, sinusitis, basophilic leukemia, chronic urticaria and basophilic leukocytosis.

12. Use of a compound according to claim 1 for manufacturing a medicament for the treatment and/or prevention of a disorder or disease associated with CRTH2 activity.

25 13. Process for controlling a disorder or disease associated with CRTH2 activity in humans and animals by administration of a CRTH2 antagonistically effective amount of a compound according to claim 1.